Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02BAW
|
|||
| Former ID |
DIB015765
|
|||
| Drug Name |
MK-6325
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 1 | [1] | |
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C42H56N6O9S
|
|||
| Canonical SMILES |
CC1(CC1)S(=O)(=O)NC(=O)C23CC2C=CCCCCCC4C(=O)N5CC(CC5C(=O)N3)OC6=NC7=C(C=CC(=C7)OC)N=C6CCCCCC8CCCC8OC(=O)N4
|
|||
| InChI |
1S/C42H56N6O9S/c1-41(20-21-41)58(53,54)47-39(51)42-24-27(42)14-8-4-3-5-9-16-32-38(50)48-25-29(23-34(48)36(49)46-42)56-37-31(43-30-19-18-28(55-2)22-33(30)44-37)15-10-6-7-12-26-13-11-17-35(26)57-40(52)45-32/h8,14,18-19,22,26-27,29,32,34-35H,3-7,9-13,15-17,20-21,23-25H2,1-2H3,(H,45,52)(H,46,49)(H,47,51)/b14-8+/t26-,27-,29-,32+,34+,35-,42-/m1/s1
|
|||
| InChIKey |
BLFKRFGLQFYXDF-WAZRELCSSA-N
|
|||
| CAS Number |
CAS 1263814-52-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus Serine protease NS4A (HCV NS4A) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01329913) Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003). U.S. National Institutes of Health. | |||
| REF 2 | Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp -sp Suzuki-Miyaura coupling and ring closing metathesis. Org Lett. 2015 Mar 20;17(6):1533-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.